pH Science Holdings

pH Science is a clinical-stage biotechnology company focused on developing next-generation precision oncology therapies using its proprietary pH-sensitive prodrug platform. The company's technology exploits the acidic microenvironment characteristic of solid tumors to achieve selective drug activation, aiming to enhance therapeutic efficacy while minimizing systemic side effects. Its lead candidate, PHS-001, is a pH-sensitive TLR7/8 agonist currently in clinical development for the treatment of advanced solid tumors. By masking the activity of potent molecules until they reach the tumor site, pH Science seeks to overcome the toxicity limitations of traditional systemic treatments. The company is supported by a syndicate of leading global healthcare investors and maintains research and development facilities in Shanghai.